Evidence map›Paper›PMID 32872523›Full record

ArticleInternational journal of molecular sciences2020

Anti-Fibrotic Effect of Human Wharton's Jelly-Derived Mesenchymal Stem Cells on Skeletal Muscle Cells, Mediated by Secretion of MMP-1.

Alee Choi, Sang Eon Park, Jang Bin Jeong, Suk-Joo Choi, Soo-Young Oh, Gyu Ha Ryu, Jeehun Lee, Hong Bae Jeon, Jong Wook Chang

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Stem/progenitor cell-based therapy for Duchenne muscular dystrophy.Frontiers in cell and developmental biology · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Regenerative mechanisms of stem cells and their clinical applications for degenerative eye diseases.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024
    Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alee ChoiStem Cell Institute, ENCell Co. Ltd., Seoul 06072, Korea.
Sang Eon ParkStem Cell Institute, ENCell Co. Ltd., Seoul 06072, Korea.ORCID 0000-0003-3315-6426
Jang Bin JeongStem Cell Institute, ENCell Co. Ltd., Seoul 06072, Korea.
Suk-Joo ChoiDepartment of Obstetrics and Gynecology, Samsung Medical Center, Seoul 06351, Korea.
Soo-Young OhDepartment of Obstetrics and Gynecology, Samsung Medical Center, Seoul 06351, Korea.
Gyu Ha RyuDepartment of Medical Device Management and Research, SAIHST, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Jeehun LeeDepartment of Pediatrics, Samsung Medical Center, Seoul 06351, Korea.
Hong Bae JeonStem Cell Institute, ENCell Co. Ltd., Seoul 06072, Korea.
Jong Wook ChangStem Cell Institute, ENCell Co. Ltd., Seoul 06072, Korea.
Samsung Medical Center · KRCell Biotech (South Korea) · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular matrix (ECM) components play an important role in maintaining skeletal muscle function, but excessive accumulation of ECM components interferes with skeletal muscle regeneration after injury, eventually inducing fibrosis. Increased oxidative stress level caused by dystrophin deficiency is a key factor in fibrosis in Duchenne muscular dystrophy (DMD) patients. Mesenchymal stem cells (MSCs) are considered a promising therapeutic agent for various diseases involving fibrosis. In particular, the paracrine factors secreted by MSCs play an important role in the therapeutic effects of MSCs. In this study, we investigated the effects of MSCs on skeletal muscle fibrosis. In 2-5-month-old mdx mice intravenously injected with 1 × 10

Indexed as

Administration, IntravenousAnimalsCell LineDipeptidesExtracellular MatrixFemaleHydrogen PeroxideMatrix Metalloproteinase 13Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMice, Inbred mdxMuscle CellsMuscle, SkeletalMuscular Dystrophy, DuchennePregnancyDipeptidesHydrogen PeroxideMatrix Metalloproteinase 13Mmp13 protein, mouseN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamideTissue Inhibitor of Metalloproteinase-1Duchenne muscular dystrophymatrix metalloproteinase-1paracrine factorskeletal muscle fibrosisWharton’s jelly-derived mesenchymal stem cell

Identifiers

PMID32872523
PMCPMC7504611
OpenAlexW3082963500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.